Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Chen Richard | Chief Medical Officer | Jun 17 | Sale | 3.29 | 1,565 | 5,149 | 146,488 | Jun 21 04:52 PM | Tachibana Aaron | Chief Financial Officer | Jun 17 | Sale | 3.29 | 3,440 | 11,318 | 231,943 | Jun 21 04:48 PM | Moore Stephen Michael | General Counsel | Jun 15 | Sale | 3.24 | 1,832 | 5,936 | 73,885 | Jun 17 05:11 PM | Chen Richard | Chief Medical Officer | Jun 15 | Sale | 3.24 | 6,818 | 22,090 | 148,053 | Jun 17 05:08 PM | Tachibana Aaron | Chief Financial Officer | Jun 15 | Sale | 3.24 | 6,818 | 22,090 | 235,383 | Jun 17 05:02 PM | Tachibana Aaron | Chief Financial Officer | Jun 02 | Sale | 3.59 | 4,187 | 15,031 | 242,201 | Jun 06 05:36 PM | Chen Richard | Chief Medical Officer | Jun 02 | Sale | 3.59 | 421 | 1,511 | 154,871 | Jun 06 05:30 PM | West John Stephen | President and CEO | May 16 | Sale | 4.86 | 2,408 | 11,703 | 382,444 | May 18 06:16 PM | Tachibana Aaron | Chief Financial Officer | May 16 | Sale | 4.86 | 1,286 | 6,250 | 246,388 | May 18 06:17 PM | Moore Stephen Michael | General Counsel | May 16 | Sale | 4.86 | 664 | 3,227 | 75,717 | May 18 06:15 PM | Chen Richard | Chief Medical Officer | May 16 | Sale | 4.86 | 1,286 | 6,250 | 155,830 | May 18 06:14 PM | Moore Stephen Michael | General Counsel | May 02 | Sale | 5.53 | 5,733 | 31,703 | 76,381 | May 04 05:38 PM | West John Stephen | President and CEO | Apr 20 | Option Exercise | 1.84 | 45,061 | 82,912 | 384,852 | Apr 22 05:25 PM | West John Stephen | President and CEO | Apr 13 | Option Exercise | 1.84 | 64,430 | 118,551 | 404,221 | Apr 15 06:24 PM | Lightspeed Venture Partners Se | Affiliate of 10% Owner | Mar 03 | Buy | 9.83 | 261,011 | 2,565,738 | 2,084,240 | Mar 04 08:27 PM | Lightspeed Venture Partners Se | Affiliate of 10% Owner | Mar 03 | Buy | 10.38 | 4,750 | 49,305 | 4,750 | Mar 04 08:27 PM | Lightspeed Venture Partners Se | Affiliate of 10% Owner | Mar 02 | Buy | 9.96 | 48,989 | 487,930 | 1,823,229 | Mar 04 08:27 PM | Chen Richard | Chief Medical Officer | Mar 02 | Sale | 10.18 | 471 | 4,795 | 157,334 | Mar 04 06:09 PM | Tachibana Aaron | Chief Financial Officer | Mar 02 | Sale | 10.18 | 4,511 | 45,922 | 251,441 | Mar 04 06:08 PM | Chen Richard | Chief Medical Officer | Jan 28 | Sale | 9.93 | 705 | 7,001 | 157,805 | Feb 01 06:05 PM | Tachibana Aaron | Chief Financial Officer | Jan 28 | Sale | 9.93 | 705 | 7,001 | 255,952 | Feb 01 06:04 PM | West John Stephen | President and CEO | Jan 19 | Sale | 11.01 | 64,503 | 710,178 | 285,457 | Jan 19 07:22 PM | West John Stephen | President and CEO | Jan 18 | Sale | 11.73 | 35,484 | 416,227 | 349,960 | Jan 19 07:22 PM | Chen Richard | Chief Medical Officer | Dec 17 | Sale | 12.80 | 1,563 | 20,006 | 158,510 | Dec 20 07:10 PM | West John Stephen | President and CEO | Dec 17 | Sale | 12.80 | 2,732 | 34,970 | 385,444 | Dec 20 07:00 PM | Tachibana Aaron | Chief Financial Officer | Dec 17 | Sale | 12.80 | 3,437 | 43,994 | 256,657 | Dec 20 07:59 PM | West John Stephen | President and CEO | Dec 16 | Sale | 13.42 | 97,268 | 1,305,337 | 388,176 | Dec 17 09:17 PM | Chen Richard | Chief Medical Officer | Dec 02 | Sale | 12.92 | 419 | 5,413 | 80,073 | Dec 06 06:06 PM | Tachibana Aaron | Chief Financial Officer | Dec 02 | Sale | 12.92 | 4,184 | 54,057 | 180,094 | Dec 06 06:05 PM | West John Stephen | President and CEO | Nov 30 | Sale | 13.65 | 100,000 | 1,365,000 | 485,444 | Dec 02 05:49 PM | West John Stephen | President and CEO | Nov 17 | Sale | 17.04 | 2,348 | 40,010 | 585,444 | Nov 19 06:15 PM | Tachibana Aaron | Chief Financial Officer | Nov 17 | Sale | 17.04 | 1,253 | 21,351 | 184,278 | Nov 19 06:14 PM | Chen Richard | Chief Medical Officer | Nov 17 | Sale | 17.04 | 1,253 | 21,351 | 79,781 | Nov 19 06:12 PM | West John Stephen | President and CEO | Oct 12 | Sale | 19.33 | 100,000 | 1,933,000 | 587,792 | Oct 14 06:24 PM | Tachibana Aaron | Chief Financial Officer | Sep 17 | Sale | 21.25 | 3,152 | 66,980 | 185,531 | Sep 21 06:36 PM | Chen Richard | Chief Scientific Officer | Sep 17 | Sale | 21.25 | 1,088 | 23,120 | 81,034 | Sep 21 06:35 PM | Tachibana Aaron | Chief Financial Officer | Sep 02 | Sale | 21.92 | 3,820 | 83,734 | 188,683 | Sep 07 05:51 PM | Chen Richard | Chief Scientific Officer | Sep 02 | Sale | 21.92 | 291 | 6,379 | 82,122 | Sep 07 05:50 PM | Chen Richard | Chief Scientific Officer | Aug 06 | Option Exercise | 0.00 | 15,564 | 0 | 102,413 | Aug 10 05:19 PM | Chen Richard | Chief Scientific Officer | Aug 06 | Sale | 21.22 | 4,436 | 94,132 | 82,413 | Aug 10 05:19 PM | West John Stephen | President and CEO | Jul 08 | Sale | 22.54 | 110,000 | 2,479,400 | 635,520 | Jul 12 05:07 PM |
|